Advances in understanding the role of sphingosine kinase-2 in tumorigenesis and its inhibitors
10.16438/j.0513-4870.2020-0014
- VernacularTitle:鞘氨醇激酶2在肿瘤中的作用及其抑制剂研究进展
- Author:
Jin-miao ZHANG
1
;
Qing-jing HAO
2
;
Kai-xuan JIANG
2
;
Li-li LI
2
;
Mao-yu ZHANG
2
;
Jin-xin WANG
2
;
Kan YANG
1
Author Information
1. College of Pharmacy, Hebei University, Hebei Key Laboratory of Drug Analysis and Quality Control, Baoding 071002, China
2. College of Pharmacy, China Pharmaceutical University, Jiangsu Provincial Key Laboratory of Drug Molecular Design and Drug Formation Optimization, Nanjing 211198, China
- Publication Type:Research Article
- Keywords:
sphingosine kinase 2;
tumor;
inhibitor;
combination
- From:
Acta Pharmaceutica Sinica
2020;55(9):2062-2069
- CountryChina
- Language:Chinese
-
Abstract:
In recent years the role of sphingosine kinase 2 (SphK2), a key enzyme in the sphingolipid pathway, in the process of tumorigenesis has gradually been elucidated. Recent research has shown that SphK2 inhibitors can be used as anticancer drugs alone or in combination with existing drugs to increase the therapeutic sensitivity of drug-resistant tumors. Among them, one selective SphK2 inhibitor, ABC294640, shows excellent oral bioavailability and biodistribution in vivo and has now entered Phase II clinical research. Therefore, developing innovative drugs based on SphK2 is of great interest. Herein, we discuss progress in understanding the role of SphK2 in tumorigenesis and review the recent development of inhibitors of SphK2.
